NUCRYST Pharmaceuticals and the Advanced Wound Management division of Smith & Nephew plc announced that the US Food & Drug Administration (FDA) granted marketing clearance for Acticoat Flex. Acticoat Flex is an antimicrobial barrier dressing designed to conform to body contours and allow for flexible movement for injuries that require sustained antimicrobial activity. Acticoat Flex represents a new addition to the Acticoat family and is coated with NUCRYST’s patented SILCRYST nanocrystalline silver technology.
“We are pleased that the FDA has granted marketing clearance for Acticoat Flex,” said David B. Holtz, Interim President and Chief Executive Officer, and Chief Financial Officer of NUCRYST. “The launch of Acticoat Flex by Smith & Nephew is the latest result of the successful partnership between Smith & Nephew and NUCRYST to provide advanced antimicrobial protection to acute trauma and burn patients, as well as to patients with complex chronic wounds.”
The Acticoat brand is a leader in the antimicrobial advanced wound care market. Acticoat Flex simplifies the dressing of wounds with its unique conformable design that easily contours to surfaces, including difficult-to-protect articulating regions such as knee or elbow joints.
“We are delighted with the US FDA clearance for Acticoat Flex. We have had excellent feedback from Canada where Acticoat Flex was launched at the end of 2008. The approval from the FDA allows us to further roll out the technology and support the fight against healthcare acquired infection” commented Roger Teasdale, President of Smith & Nephew’s Advanced Wound Management business. “This product launch is a key to our focus on Infection Management, one of the three focused elements of the Wound Management Global Business Unit strategy along with Exudate Management and Negative Pressure Wound Therapy.”